Ri Liesner

12.1k citations
123 papers · 6.7k · 2 hit papers · h-index 44

Impact in

  • Hematology top 0.05%
    • Hemophilia Treatment and Research
    • Platelet Disorders and Treatments
    • Blood Coagulation and Thrombosis Mechanisms
    • Hemostasis and retained surgical items
    • Blood groups and transfusion
  • Genetics top 0.5%
    • Coagulation, Bradykinin, Polyphosphates, and Angioedema

Papers in

    • Hemophilia Treatment and Research 70
    • Platelet Disorders and Treatments 36
    • Blood Coagulation and Thrombosis Mechanisms 36
    • Chronic Myeloid Leukemia Treatments 6
    • Coagulation, Bradykinin, Polyphosphates, and Angioedema 9
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 8
    • Blood disorders and treatments 8

Ri Liesner

120 papers receiving 6.5k citations

Ri Liesner's Hit Papers

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors 2019 · 268 citations
2680+4+9Years since publication100200300400500

Peers

Ri Liesner
Comparison fields: 5 of 109
  • Hematology 4.9k
  • Genetics 1.2k
  • Internal Medicine 233
  • Nephrology 450
  • Immunology 1.3k
Replace Francesco Rodeghiero with:
Francesco Rodeghiero Italy
Paul Knöbl Austria
Rob Fijnheer Netherlands
Bertrand Godeau France
Roberto Stasi Italy
Terry Gernsheimer United States
Ralph A. Gruppo United States
P.M. Mannucci Italy
Abdulgabar Salama Germany
Diane J. Nugent United States
Ri Liesner relative to Francesco Rodeghiero Italy Francesco Rodeghiero's profile →
Citations per field
00.5×1.5×
Francesco Rodeghiero · 1×
Citations per year

Countries citing papers authored by Ri Liesner

Since Specialization
Citations

This map shows the geographic impact of Ri Liesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ri Liesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ri Liesner more than expected).

Fields of papers citing papers by Ri Liesner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ri Liesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ri Liesner. The network helps show where Ri Liesner may publish in the future.

Co-authors

The 25 scholars most cited alongside Ri Liesner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ri Liesner Line = papers co-authored together Ri Liesner links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 123 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
Hit paper breakdown →
2012561
2 2006481
3 2011278
4
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Hit paper breakdown →
2019268
5 2008259
6 2006236
7 2006219
8 2012162
9 1996161
10 2015144
11 1999143
12 2011140
13 2007128
14 2003123
15 2008121
16 2011114
17 200195
18 201095
19 201391
20 201288

About Ri Liesner

Ri Liesner is a scholar working on Hematology, Genetics, Immunology, Molecular Biology and Genetics, having authored 123 papers that have together received 6.7k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (70 papers), Platelet Disorders and Treatments (36 papers), Blood Coagulation and Thrombosis Mechanisms (36 papers), Complement system in diseases (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Blood disorders and treatments (8 papers) and Chronic Myeloid Leukemia Treatments (6 papers). The work is most often cited by research in Hematology (4.9k citations), Genetics (1.2k citations), Internal Medicine (233 citations), Nephrology (450 citations) and Immunology (1.3k citations). Ri Liesner has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Peter W. Collins, Kate Khair, Ian Hann, C. R. M. Hay, Samuel J. Machin, Ian Mackie, Marie Scully, Elizabeth Chalmers, David Keeling and Paul Harrison. Their work appears in journals such as Haemophilia, British Journal of Haematology, Blood, Journal of Thrombosis and Haemostasis and Blood Coagulation & Fibrinolysis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact